Precision Oncology
The latest news on biomarker-guided cancer care.
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy while Personalis completes its clinical validation in more indications.
Carisma Therapeutics to Start Phase I Trial of CAR Monocyte in HER2-Positive Cancers
The FDA cleared the firm's investigational new drug application to study its autologous cell therapy CT-0525 in patients with solid tumors overexpressing HER2.
Candel Therapeutics Lays off Half its Workforce, Refocuses on Most Advanced Oncology Programs
By reducing staff and lowering its operating costs, Candel expects to fund operations into the fourth quarter of 2024.
Autolus Seeks FDA Approval for CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia
The firm's supplemental biologics license application is based on encouraging data from a Phase II trial in more than 100 patients.
The researchers hope to reproduce in a prospective clinical trial the model's 70 percent to 80 percent accuracy for predicting immunotherapy response.
Nov 17, 2023